CD19 is worth $700m to Merck
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
Umoja and AbbVie chase Interius with in vivo Car-T
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
Gilead’s multiple bets on fast Car production
A three-way race is on to determine which Car-T therapy Gilead will take into pivotal trials.
Regeneron gets a European reprieve
The EU recommendation for odronextamab comes after a US rejection in March.
EHA 2024 – J&J bows out as Roche looks to confirm
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
FDA knocks back Regeneron’s CD20 T-cell engager
The decision highlights the fact that Regeneron is still doing dose-finding work for odronextamab.
